# Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

> **NCT00624338** · PHASE2,PHASE3 · COMPLETED · sponsor: **EMD Serono** · enrollment: 461 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Atacicept 75 mg
- **DRUG:** Atacicept 150 mg
- **OTHER:** Placebo Comparator

## Key facts

- **NCT ID:** NCT00624338
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-10
- **Target enrollment:** 461 (ACTUAL)
- **Last updated:** 2016-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00624338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00624338, "Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00624338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*